Status:

COMPLETED

Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients

Lead Sponsor:

University of Michigan

Collaborating Sponsors:

Gilead Sciences

Conditions:

End-stage Renal Disease

Cardiovascular Disease

Eligibility:

All Genders

18-74 years

Phase:

PHASE4

Brief Summary

End-stage renal disease (ESRD) patients often develop cardiovascular complications, and cardiovascular disease is the leading cause of death in this population. Ranolazine's ability to treat angina wi...

Eligibility Criteria

Inclusion

  • 18-74 years of age
  • Within 50% of ideal body weight and greater than 40 kg
  • Chronic kidney disease (CKD) stage 5 receiving maintenance hemodialysis for at least 3 months
  • Native kidney estimated glomerular filtration rate(GFR) \< 10 mL/min
  • No concurrent illness or evidence of infection
  • Able to give informed consent

Exclusion

  • QTc interval \> 470 msec at echocardiogram (ECG) obtained within the last 6 months
  • Concomitant QT-prolonging drugs, major P-gp inhibitors, and CYP3A4 inducers and inhibitors including: cyclosporine, rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, St. John's Wort, ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, saquinavir, quinidine, dofetilide, sotalol, amiodarone, erythromycin, thioridazine, ziprasidone, haloperidol, trimethoprim/sulfamethoxazole, ciprofloxacin, norfloxacin, levofloxacin, moxifloxacin
  • Pre-study hemoglobin \< 9.5 g/dL
  • Plasma albumin \< 2.5 g/dL
  • Liver disease - exclude subjects with a Child Pugh score of C or higher
  • Positive pregnancy test
  • Breastfeeding
  • Allergy to ranolazine
  • Participating in another investigational study
  • Hepatitis B infection due to dialysis isolation requirements
  • Unstable blood pressure control
  • Need for routine large fluid removal during dialysis (\> 4L)

Key Trial Info

Start Date :

October 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2013

Estimated Enrollment :

17 Patients enrolled

Trial Details

Trial ID

NCT01435174

Start Date

October 1 2011

End Date

March 1 2013

Last Update

October 16 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Michigan Hospital

Ann Arbor, Michigan, United States, 48109